ClinicalTrials.gg
CompletedNCT07948798MINI vs PCDAIUpdated Nov 19, 2026

Comparative Study of Clinical Activity Indices of Crohn's Disease Patients Treated at Gazi University Pediatric Gastroenterology Clinic.

An observational study in Crohn's Disease (CD), sponsored by Gazi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Gazi University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 55 studies in Crohn Disease with a site in Turkey — 10 open to participants now, 20 under way, 15 of them phase 3. Crohn Disease · Turkey.

Started
2024
with 8 others
Observational
6 of 55
2 open now
Registered
55th of 55
by date
Lead sponsor
3 of 55
Gazi University

Among the 55 studies in Crohn Disease with a site in Turkey, this one is one of 9 that started in 2024, is one of 6 observational ones, and was the 55th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 55 studies in Crohn Disease with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease with a site in Turkey, or all of them as a file.
02

Study summary

Crohn's disease (CD) is a chronic inflammatory bowel disease that requires long-term monitoring. Although endoscopy is the gold standard for assessing intestinal inflammation, its invasive nature limits repeated use, particularly in children. Therefore, reliable noninvasive methods are needed to monitor disease activity.

This single-center, prospective observational study aims to evaluate the performance of the Mucosal Inflammation Noninvasive Index (MINI) and the Pediatric Crohn's Disease Activity Index (PCDAI) in children with Crohn's disease.

The study examines the relationship between MINI and PCDAI and evaluates their associations with endoscopic disease activity measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD). It also compares the ability of both indices to identify patients with active intestinal inflammation.

The initial research hypothesis focused on evaluating the correlation between MINI and PCDAI. During the ongoing data collection period, the hypothesis was expanded to investigate whether MINI demonstrates superior discriminative performance compared with PCDAI in identifying endoscopic disease activity as assessed by SES-CD.

Read the detailed description

Crohn's disease (CD) is a lifelong, chronic inflammatory bowel disease. Endoscopic evaluation is the gold standard for assessing mucosal inflammation; however, it is invasive. This increases the need for reliable noninvasive tools, particularly in pediatric patients. The Mucosal Inflammation Noninvasive Index (MINI) was developed for this purpose. It aims to predict mucosal inflammation by jointly evaluating stool characteristics, fecal calprotectin, erythrocyte sedimentation rate, and C-reactive protein levels. This study has three aims in pediatric patients with CD. The first is to evaluate the relationship between MINI and the Pediatric Crohn's Disease Activity Index (PCDAI). The second is to examine how each index relates to endoscopic disease activity, as determined by the Simple Endoscopic Score for Crohn's Disease (SES-CD), in assessments that include endoscopy. The third is to compare how well the two indices discriminate endoscopically active disease. Ultimately, the study aims to determine whether MINI demonstrates superior performance to PCDAI in discriminating endoscopically active disease in pediatric patients with CD.

03

Conditions studied

  • Crohn's Disease (CD)

Browse trials for

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This single-center, observational, prospective study was conducted in the Department of Pediatric Gastroenterology at Gazi University Hospital between November 2024 and July 2026. It included patients who had been diagnosed with CD according to the revised Porto/ESPGHAN criteria and were followed up in our department, and met the study eligibility criteria.

Eligibility criteria

**Inclusion Criteria:**

  • Diagnosis of Crohn's disease.
  • Availability of the clinical, laboratory, and endoscopic data required to calculate the MINI, PCDAI, and SES-CD scores.
  • Written obtained from a parent or legal guardian, and assent from the patient when age-appropriate.

**Exclusion Criteria:**

  • Declined to participate in the study.
  • Incomplete medical records.
  • Referral to our department solely for ileocolonoscopy.
  • Diagnosis of ulcerative colitis.
  • Diagnosis of Crohn's disease established by double-balloon enteroscopy (DBE).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (actual)
Patient registry
No

Groups and cohorts

  • Pediatric Patients with Crohn's Disease

    Seventy pediatric patients diagnosed with Crohn's disease were included in this prospective observational study. Disease activity was evaluated using MINI and PCDAI, and their relationships with endoscopic activity assessed by SES-CD were investigated.

06

What researchers measure

Primary outcomes

  1. Correlation Between MINI and PCDAI in Pediatric Crohn's Disease

    Time frame: 20 months

07

Study locations

1 site
  • Gazi University Faculty of Medicine
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jul 2026, 19 months.

Of 231 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's 19 months is below that.

Counting every sponsor, half of 304 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 19, 2026
StartActual
Nov 25, 2024
Primary completionActual
Jul 20, 2026
CompletionActual
Jul 20, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948798
Lead sponsor
Gazi University
Responsible party
Ödül EGRİTAS (professor, Gazi University) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 25, 2024
Primary completion
Jul 20, 2026
Completion
Jul 20, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion